Medicilon appeared at the 25th SAPA-NE Annual Conference

On June 3, 2023, the 25th annual conference of SAPA-NE (Sino-American Pharmaceutical Professionals Association–New England/Boston) was successfully held in Boston, MA. Dr. Chunlin Chen, CEO of Medicilon, Dr. Zhenrong Guo, Executive Vice President of Pharmaceutical Research, and the Medicilon US team attended the annual conference and had pleasant and in-depth exchanges with many guests and experts during the conference. With professional quality, confident demeanor, and exhibitions as a platform, Medicilon fully demonstrates and delivers the values of "focus on innovation, win-win collaboration, client first, and loving and dedication". During the conference, the Medicilon team conducted in-depth exchanges with a lot of pharmaceutical colleagues, and discussed about the industry situation and market prospects.

From left to right Cindy Chen, Dr. Jun Li, Dr. Chunlin Chen, Dr. Zhenrong Guo, Dr. Yan Zhou.webp

From left to right: Cindy Chen, Dr. Jun Li, Dr. Chunlin Chen, Dr. Zhenrong Guo, Dr. Yan Zhou

Dr. Chunlin Chen of Medicilon was invited to give a wonderful speech on "Medicilon Strategy & 20 Years Experience for Dual Filing of IND to US FDA & China NMPA along with IPO at STAR Market". Since its establishment in 2004, Medicilon has provided drug R&D services to more than 2,000 clients around the world during the 20-year milestone. More than 330 new drug and generic drug projects that have participated in the research and development have obtained IND approval. In the past 20 years, Medicilon has grown together with the partners around the world.

Dr. Chen shared an in-depth analysis and case study.webp

Based on Medicilon's nearly 20 years of experience in IND filing, Dr. Chen shared an in-depth analysis and case study.

The 25th SAPA-NE Annual Conference attracted many professionals from the biotechnology and pharmaceutical industries to attend. Through intensive exchanges and discussion, the participants had in-depth discussion with industry organizations on how to meet the transformation in this challenging situation. Participants exchanged views on new trends in the industry in terms of new drug R&D, AI pharmaceuticals, technological innovation, pharmaceutical investment, and regulatory oversight.

The audience listened to Dr. Chen's speech.webp

The audience listened to Dr. Chen's speech.

As the Diamond Sponsor of the 25th SAPA-NE Annual Conference, the dinner event was exclusively sponsored by Medicilon. The well-arranged drinks and snacks allowed participants to enjoy the opportunity to communicate with different professionals after a busy meeting. The buffet dinner drew a perfect end to the busy day of business negotiation.

Medicilon, as a professional biopharmaceutical preclinical R&D service CRO, provides global pharmaceutical companies and research institutions with a full range of one-stop new drug R&D services that meet both China and US filing standards. Through this exhibition, the influence of the Medicilon has been further enhanced internationally. In order to realize the vision of "providing a full range of preclinical research services for global pharmaceutical companies, research institutions and all scientific researchers, and promoting the process of new drug research", Medicilon will continue to deepen the overseas high-end market, explore the European and American markets, and accelerate the pace of internationalization.

In Vitro Enzyme Activity Assay

Kinases play extensive and important roles in signal transduction and co-ordination of complex functions. Currently, about 300 kinase inhibitors have been approved for marketing, among which receptor tyrosine kinase (RTK) inhibitors are the main ones. Medicilon provides high-quality kinase profile screening and has one-stop kinase research services from assay development, high-throughput screening to selectivity analysis. In addition, Medicilon provides many other enzyme activity screens. Wide Variety Provides 200+ in vitro enzymatic detection methods; 100+ kinases, including CTK, RTK, AGC, CMGC and other kinase families as well as important common mutations Project Flexibility Various types of plates for screening, such as 96 and 384; Multiple flexible kinase profiles, including TK kinase family, CDK kinase family, etc., to meet different customer customization needs. Various Methods Fluorescence detection; Chemiluminescence detection; Absorbance detection LanthaScr...

阅读全文

Fluorescence Probes Synthesis

Medicilon's fluorescent probes and labeling platforms can provide fluorescent probe design and synthesis services for scientific institutions, drug R&D companies, and other customers. Design and synthesis steps Fluorescent probes are tools used to detect, measure and analyze biomolecules, cells and tissues. They achieve these purposes by emitting and receiving fluorescent signals. Medicilon can complete the design and synthesis of fluorescent probes for biomolecules. Selection of target molecules and determination of target. Selection of fluorescent dyes. Design of molecular structure. Synthesize probe molecules. Testing the properties of probe molecules. Custom synthesis Medicilon's fluorescent probes and labeling platforms can provide fluorescent probe design and synthesis services for scientific institutions, drug R&D companies, and other customers. After years of development, Medicilon's fluorescent probes and labeling platforms have accumulated rich experience...

阅读全文

Custom Synthesis

Medicilon has synthesized over 10,000 individual compounds from gram to kilogram quantities, and many compounds are synthesized with more than ten synthetic steps. The overall synthesis success rate is over 95%. High quality products from mg to kg scale Reagents, intermediates, building blocks, and scaffolds Preparation of API or reference standards Development of synthetic routes for impurities and metabolites On-site analytical support Product delivered with COA Medicilon offers integrated drug discovery services -- Chemistry, Biology & Preclinical Services

阅读全文

Shanghai Medicilon Inc.

搜索此博客